MA30798B1 - Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 - Google Patents

Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1

Info

Publication number
MA30798B1
MA30798B1 MA31794A MA31794A MA30798B1 MA 30798 B1 MA30798 B1 MA 30798B1 MA 31794 A MA31794 A MA 31794A MA 31794 A MA31794 A MA 31794A MA 30798 B1 MA30798 B1 MA 30798B1
Authority
MA
Morocco
Prior art keywords
antigonists
crf1 receptor
pyrazolopyrimidines
thiazole
thiazole pyrazolopyrimidines
Prior art date
Application number
MA31794A
Other languages
English (en)
Inventor
Zhaogen Chen
Chafiq Hamdouchi Hamdouchi
Erik James Hembre
Philip Arthur Hipskind
Jason Kenneth Myers
Takako Takakuwa
James Lee Toth
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30798(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA30798B1 publication Critical patent/MA30798B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I), DES COMPOSITIONS PHARMACEUTIQUES À BASE DE CES COMPOSÉS, ET LEUR UTILISATION COMME ANTAGONISTES DU RÉCEPTEUR DU CRF1 (FACTEUR 1 DE LIBÉRATION DE LA CORTICOTROPINE) POUR LE TRAITEMENT DE TROUBLES PSYCHIATRIQUES ET NEUROENDOCRINIENS, DE MALADIES NEUROLOGIQUES ET DU SYNDROME MÉTABOLIQUE.
MA31794A 2006-09-20 2009-04-16 Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 MA30798B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20

Publications (1)

Publication Number Publication Date
MA30798B1 true MA30798B1 (fr) 2009-10-01

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31794A MA30798B1 (fr) 2006-09-20 2009-04-16 Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1

Country Status (34)

Country Link
US (1) US8030304B2 (fr)
EP (1) EP2094709B1 (fr)
JP (1) JP5161226B2 (fr)
KR (1) KR101088239B1 (fr)
CN (1) CN101516887B (fr)
AR (1) AR062886A1 (fr)
AT (1) ATE481405T1 (fr)
AU (1) AU2007297421B2 (fr)
BR (1) BRPI0717023B8 (fr)
CA (1) CA2663511C (fr)
CL (1) CL2007002693A1 (fr)
CR (1) CR10682A (fr)
CY (1) CY1110854T1 (fr)
DE (1) DE602007009305D1 (fr)
DK (1) DK2094709T3 (fr)
EA (1) EA015179B1 (fr)
ES (1) ES2350282T3 (fr)
HK (1) HK1132505A1 (fr)
HR (1) HRP20100516T1 (fr)
IL (1) IL197614A (fr)
MA (1) MA30798B1 (fr)
MX (1) MX2009003125A (fr)
MY (1) MY146388A (fr)
NO (1) NO20091489L (fr)
NZ (1) NZ575572A (fr)
PE (1) PE20081377A1 (fr)
PL (1) PL2094709T3 (fr)
PT (1) PT2094709E (fr)
RS (1) RS51545B (fr)
SI (1) SI2094709T1 (fr)
TN (1) TN2009000095A1 (fr)
TW (1) TWI402269B (fr)
UA (1) UA96458C2 (fr)
WO (1) WO2008036579A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
PT2350079E (pt) * 2008-10-02 2012-12-20 Lilly Co Eli Compostos tiazolil-pirazolopirimidina como intermediários de síntese e processos de síntese relacionados
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
CA3155599A1 (fr) * 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Antagonistes du recepteur crf1 pour le traitement de l'hyperplasie surrenalienne congenitale
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CN109906222B (zh) 2016-09-07 2023-08-01 加利福尼亚大学董事会 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
MX2019015320A (es) * 2017-08-14 2020-07-20 Spruce Biosciences Inc Antagonistas del receptor del factor liberador de corticotropina.
AU2018318990B2 (en) * 2017-08-14 2023-01-05 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
AU2019260793B2 (en) * 2018-04-27 2023-05-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
EP4069697A1 (fr) * 2019-12-04 2022-10-12 Neurocrine Biosciences, Inc. Antagonistes du récepteur crf et procédés d'utilisation
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
BR112023002497A2 (pt) 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos
EP4203964A1 (fr) 2020-08-26 2023-07-05 Neurocrine Biosciences, Inc. Antagonistes du récepteur crf et méthodes d'utilisation
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
CA3235958A1 (fr) * 2021-11-19 2023-05-25 Spruce Biosciences, Inc. Composition cristalline de tildacerfont et ses methodes d'utilisation et de preparation
WO2023163945A1 (fr) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2895961B2 (ja) 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
TR199800792T2 (xx) * 1996-02-07 1998-07-21 Janssen Pharmaceutica N.V. CRF resept�r antagonistleri olarak pirazolopirimidinler.
EA006626B1 (ru) 1996-07-24 2006-02-24 Дюпон Фармасьютикалз Компани Азолопиримидины, фармацевтическая композиция и способ лечения
PL195762B1 (pl) * 1996-07-24 2007-10-31 Bristol Myers Squibb Pharma Co Związki [1,5-a]pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie związków [1,5-a]pirazolo-1,3,5-triazynowych do wytwarzania leku
HUP9903965A3 (en) 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
EP1040831A3 (fr) * 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU4203500A (en) * 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
IL148904A0 (en) * 1999-09-30 2002-09-12 Neurogen Corp Amino substituted pyrazolo {1,5,-a}-1,5- pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
SK287603B6 (sk) * 2001-03-13 2011-03-04 Bristol-Myers Squibb Pharma Company 4-(2-Butylamino)-2,7-dimetyl-8-(2-metyl-6-metoxypyrid-3- yl)pyrazol-[1,5-a]-1,3,5-triazín, farmaceutická kompozícia obsahujúca túto zlúčeninu, použitie tejto zlúčeniny v terapii a na prípravu farmaceutickej kompozície a výrobok obsahujúci túto zlúčeninu
MY143499A (en) 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto

Also Published As

Publication number Publication date
US20100222339A1 (en) 2010-09-02
KR101088239B1 (ko) 2011-11-30
EP2094709B1 (fr) 2010-09-15
MY146388A (en) 2012-08-15
EP2094709A1 (fr) 2009-09-02
DE602007009305D1 (de) 2010-10-28
CR10682A (es) 2009-08-13
JP5161226B2 (ja) 2013-03-13
BRPI0717023A2 (pt) 2014-03-11
CA2663511A1 (fr) 2008-03-27
ES2350282T3 (es) 2011-01-20
AU2007297421B2 (en) 2012-03-08
CN101516887B (zh) 2011-11-02
HRP20100516T1 (hr) 2010-10-31
PL2094709T3 (pl) 2011-02-28
PE20081377A1 (es) 2008-09-18
RS51545B (en) 2011-06-30
NO20091489L (no) 2009-04-16
EA015179B1 (ru) 2011-06-30
CY1110854T1 (el) 2015-06-10
TN2009000095A1 (en) 2010-08-19
AR062886A1 (es) 2008-12-10
CL2007002693A1 (es) 2008-04-18
UA96458C2 (ru) 2011-11-10
DK2094709T3 (da) 2010-12-06
NZ575572A (en) 2011-10-28
AU2007297421A1 (en) 2008-03-27
IL197614A (en) 2012-10-31
SI2094709T1 (sl) 2011-01-31
ATE481405T1 (de) 2010-10-15
JP2010504344A (ja) 2010-02-12
TW200821312A (en) 2008-05-16
IL197614A0 (en) 2009-12-24
CA2663511C (fr) 2012-12-04
US8030304B2 (en) 2011-10-04
WO2008036579A1 (fr) 2008-03-27
EA200970303A1 (ru) 2009-10-30
PT2094709E (pt) 2010-10-04
BRPI0717023B1 (pt) 2019-11-19
BRPI0717023B8 (pt) 2021-05-25
TWI402269B (zh) 2013-07-21
CN101516887A (zh) 2009-08-26
HK1132505A1 (en) 2010-02-26
MX2009003125A (es) 2009-05-28
KR20090052366A (ko) 2009-05-25

Similar Documents

Publication Publication Date Title
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
CR9389A (es) Compuestos de imidazopiridazina
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
GEP20104962B (en) Fused heterocyclic compounds
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
JO2686B1 (en) Vehicles
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MX2009005252A (es) Aminopirrolidinas como antagonistas del receptor de quimiocina.
MX2009013733A (es) Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1.
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
EA200700909A1 (ru) Азаиндолкарбоксамиды
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
MX2007011280A (es) Dipirazoles como farmacos del sistema nervioso central.
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors